S. Koreans Report New Drug To Suppress Key Liver Cancer Protein
This article was originally published in PharmAsia News
South Korean researchers say they have developed a treatment capable of suppressing the protein behind much liver cancer. A published study said the TSAHC treatment is aimed at TM4SF5, the protein already known to be a major cause of the cancer. The substance, which is about to enter clinical trials in South Korea and the United States, has shown to have fewer side effects than drugs already available. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.